Biocon chairperson Kiran Mazumdar-Shaw on Wednesday sought a five-year exemption from drug price control and asked the government to desist from “ad hoc” measures to help the pharmaceutical sector acquire scale and become competitive in the global market.
Pfizer Inc. today announced that the merger agreement between Pfizer and Allergan plc has been terminated by mutual agreement of the companies. The decision was driven by the actions announced by the US Department of Treasury on April 4, 2016, which the companies concluded qualified as an “Adverse Tax Law Change” under the merger agreement.
Biocon chairperson Kiran Mazumdar-Shaw on Wednesday sought a five-year exemption from drug price control and asked the government to desist from “ad hoc” measures to help the pharmaceutical sector acquire scale and become competitive in the global market.
The Centre can ban even those drugs approved by the highest drug regulatory authority, the government maintained at the Delhi High Court on Wednesday in defense of its ban on several combination drugs last month, said a lawyer present at the proceedings. The court has, meanwhile, extended by nearly two more weeks the stay on the ban of the brands using these combinations, added the lawyer, who is representing a large pharmaceutical firm in the hearings. (ET)Justifying its recent ban on 344 combination drugs, the central government told the Delhi high court on Wednesday that it was a “legislative exercise” that was not influenced by earlier approvals granted by the Drug Controller General of India (DCGI), a body which operates under the central act governing medicines in India.
The Drug Price Control Order (DPCO) 2013 that expanded the span of regulation to 60% of the $22-billion Indian pharmaceutical market appears to have come a cropper. A recent study confirmed what many analysts feared: That regulation of the kind prevalent now could dent access to medicines, an outcome opposite to what the government wants.
Dr Reddy's Laboratories US arm is recalling 3,342 vials of anti-osteoporosis injection, made by Gland Pharma, according to reports.
Cipla has set its sights on building a pipeline of speciality drugs in the United States. The company, India's third-largest drugmaker, plans to deploy more funds for research and development in respiratory, dermatology, neurology and oncology segments and hopes for the first commercial launch in the US around 2020.
Asserting that regulatory action by the US Food and Drug Administration (USFDA) on leading Indian firms has impacted exports from the country, Dr Reddy's Laboratories Chairman Satish Reddy today asked for a dialogue between government and US health regulator.
The government has decided to relax a number of norms on environment clearances related to bulk drug manufacturing to encourage Indian drug makers and reduce the country’s dependence on Chinese imports.
Biocon chairperson Kiran Mazumdar-Shaw on Wednesday sought a five-year exemption from drug price control and asked the government to desist from “ad hoc” measures to help the pharmaceutical sector acquire scale and become competitive in the global market.
The Centre can ban even those drugs approved by the highest drug regulatory authority, the government maintained at the Delhi High Court on Wednesday in defense of its ban on several combination drugs last month, said a lawyer present at the proceedings. The court has, meanwhile, extended by nearly two more weeks the stay on the ban of the brands using these combinations, added the lawyer, who is representing a large pharmaceutical firm in the hearings. (ET)Justifying its recent ban on 344 combination drugs, the central government told the Delhi high court on Wednesday that it was a “legislative exercise” that was not influenced by earlier approvals granted by the Drug Controller General of India (DCGI), a body which operates under the central act governing medicines in India.
The Drug Price Control Order (DPCO) 2013 that expanded the span of regulation to 60% of the $22-billion Indian pharmaceutical market appears to have come a cropper. A recent study confirmed what many analysts feared: That regulation of the kind prevalent now could dent access to medicines, an outcome opposite to what the government wants.
Dr Reddy's Laboratories US arm is recalling 3,342 vials of anti-osteoporosis injection, made by Gland Pharma, according to reports.
Cipla has set its sights on building a pipeline of speciality drugs in the United States. The company, India's third-largest drugmaker, plans to deploy more funds for research and development in respiratory, dermatology, neurology and oncology segments and hopes for the first commercial launch in the US around 2020.
Asserting that regulatory action by the US Food and Drug Administration (USFDA) on leading Indian firms has impacted exports from the country, Dr Reddy's Laboratories Chairman Satish Reddy today asked for a dialogue between government and US health regulator.
The government has decided to relax a number of norms on environment clearances related to bulk drug manufacturing to encourage Indian drug makers and reduce the country’s dependence on Chinese imports.
No comments:
Post a Comment